Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
Holding GERN?
Track your performance easily
GERN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.64 - $5.34
Previous Close$3.49
Volume26.32M
Average Volume (3M)8.34M
Market Cap
$2.21B
Enterprise Value$1.96B
Total Cash (Recent Filing)$339.77M
Total Debt (Recent Filing)$87.26M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 06, 2025EPS Estimate
-$0.03Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding604,501,016
10 Day Avg. Volume7,703,667
30 Day Avg. Volume8,343,038
Standard Deviation0.18
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)7.27
Price to Sales (P/S)75.05
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue66.48
Enterprise Value/Gross Profit8.27K
Enterprise Value/Ebitda-10.62
Forecast
1Y Price Target
$7.63Price Target Upside118.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Geron News
PremiumCompany Announcements
Geron Corporation’s Q3 2024: Strong RYTELO Launch and Financial Growth
Bulls Say, Bears Say
Bulls Say
Healthcare CoverageCoverage of Rytelo is progressing well, with coverage policies implemented for about 70% of US covered lives, showing strong support from payors.
Market PerformanceRytelo achieved $28.2MM in its first full quarter, which is a great result as it exceeded consensus by ~$8MM and even beat investor expectations of $25MM.
Regulatory ApprovalThe EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Rytelo in patients with LR-MDS who are ESA.
Bears Say
Investor SentimentSome investors feel the company undersold the Rytelo royalty given the math implies a high IRR to the royalty purchaser.
Product Launch StrategyDue to the high costs associated with launching a new product ex-US, Geron is carefully selecting which countries it plans to commercialize Rytelo.
Regulatory And Competitive RisksKey risks include clinical failure or underperformance of imetelstat in myelofibrosis, delays to clinical timelines, failure to gain regulatory approval, and competitive pressures.
---
Ownership Overview
0.15% Insiders
13.10% Mutual Funds
41.07% Other Institutional Investors
31.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.64 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Currently, no data Available
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Mar 06, 2025 which is in 74 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Nov 07, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.084 by $0.044.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.149 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -$0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 604,501,040 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.084. Following the earnings report the stock price went up 0.468%.
Which hedge fund is a major shareholder of Geron Corp?
Among the largest hedge funds holding Geron Corp’s share is RA Capital Management. It holds Geron Corp’s shares valued at 147M.
---
Geron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.63 (118.62% Upside)
$7.63 (118.62% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 37.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
61.57%
12-Months-Change
Fundamentals
Return on Equity
-69.03%
Trailing 12-Months
Asset Growth
7.73%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
GERN Company Deck
---
GERN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong start for RYTELO's market presence, successful financial strategies, and promising growth potential both in the U.S. and internationally. However, high operating expenses and the dependency on market success pose challenges.Read More>---
GERN Stock 12 Month Forecast
Average Price Target
$7.63
▲(118.62% Upside)
Technical Analysis
Best Analysts Covering GERN
1 Year
1 Year Success Rate
14/21 ratings generated profit
1 Year Average Return
+42.48%
reiterated a buy rating 5 months ago
Copying Kalpit Patel's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +42.48% per trade.
---